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Crossed affinoimmunoelectrophoresis using conca-
navalin A and Aleuria auran tia  lectin as diantennary 
glycan- and fucose-specific affinocomponents, respec­
tively, was applied to study changes in the concentra­
tion and glycosylation of the acute phase protein ox­
acid glycoprotein (AGP) in  sera obtained from pa­
tients w ith hyperimmunoglobulinemia D and periodic 
fever syndrome. Increases in  concentration of AGP 
compared to control values were found not only dur­
ing attacks, but also during remissions. Compared to 
healthy controls, the presence of diantennary glycan- 
containing glycoforms of AGP also increased during 
febrile attacks, w hile no changes were found during 
rem issions. A continuous high degree of a l —> 3 fuco- 
sylation was accom panied by a continuous high ex­
pression of sialyl Lewisx on AGP. Despite the clinical 
picture o f recurrent febrile attacks with asymptomat­
ic intervals, these studies indicate that hyperimmuno- 
globulinem ia D should be considered a condition of
persistent inflammation. «/) 1995 Academic Press, Inc.
INTRODUCTION
Hyperimmunoglobulinemia D and periodic fever (hy­
per Igl) syndrome)1 is a syndrome characterized by 
recurrent febrile attacks, usually of very early onset 
(during the first year of life) and a constantly elevated 
polyclonal serum IgD level Since the first description 
of the hyper-IgD syndrome (1), the diagnosis has been 
made in up to 56 patients mainly from Europe in a
collaborative study by the Hyperimmunoglobulinemia
D Study Group (2-4). The attacks are characterized by 
an acute onset of high spiking fever, often preceded by 
cold chills. Abdominal complaints, vomiting, diarrhea,
tion rate; GRP, C-reactive protein; AT, ^-antitrypsin; ] 
kin 1; IL-6 , interleukin-6 ; TNF, tumor necrosis factor.
headache, and arthralgias are associated with the ep­
isodes. During the attacks, swollen, tender lymph 
nodes are often found. Especially in the young age 
group, splenomegaly may be found. Nondestructive re­
current arthritis can be demonstrated in more than 
60% of the patients (4). During the attacks, most pa­
tients have skin lesions due to cutaneous vasculitis (3). 
Typical attacks occur every 4 to 8 weeks and last 3 to 7 
days each. Laboratory testing during attacks reveals 
an acute phase response (leukocytosis, neutrophilia, 
and increasing erythrocyte sedimentation rate (ESR)). 
The diagnosis is based on the clinical picture and the 
elevated serum IgD level (>100 U/ml). The pathogene­
sis of the syndrome remains to be elucidated and no 
treatment is known.
During remissions the concentration of C-reactive 
protein, a well-known marker of an acute phase reac­
tion, returns to normal levels, although it is elevated 
during attacks (4). It is unclear as yet whether the 
syndrome is characteristic for an acute state of inflam­
mation, or whether there is a state of persistent inflam­
mation. It has been shown in several types of inflam­
mation that the glycosylation of acute phase proteins 
changes during acute and chronic inflammatory pro­
cesses (5). ar Acid glycoprotein (AGP, orosomucoid) is a 
positive acute phase protein with five N-linked glycans. 
At least 12 glycoforms of AGP can be detected in nor­
mal human serum differing in degree of branching, fu- 
cosylation, and sialylation of the glycans. The glyco­
forms containing one or more diantennary glycans are 
increased in concentration during acute inflammation. 
This occurs after acute trauma (6-9) or can appear 
with intercurrent infections, as have been described in 
rheumatoid arthritis (10, 12). In chronic inflammation 
such as rheumatoid arthritis, however, only minor 
changes could be established (10, 11). Cytokines like 
IL-1, IL-6, and TNF are involved in the inflammatory 
response and have been shown to affect the glycosyla­
tion process in the liver (12-14). Besides the changes in 
diantennary glycan content, we have recently reported
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increases in. the a l —> 3 fucosylation of AGP, during 
both acute (15) and chronic inflammation (16, 17). The 
high degree of a l —> 3 fucosylation in patients with 
rheumatoid arthritis could be returned to a lower level 
by means of treatment with methotrexate (17). This 
increase in fucosylation has also been described for 
haptoglobin (17-19) and ^-antitrypsin (AT) (17). The 
increased a l —> 3 fucosylation was accompanied by an 
increased expression of blood group determinant sialyl
Lewisx (SLeX; NeuAca2 -» 3Gal/31 —» 4 (Fucal —» 3)- 
GlcNAc-R) (16). Therefore, the type of glycosylation of 
the acute-phase protein AGP can give more informa­
tion about the state of inflammation and can serve as a 
better marker for discrimination between acute and 
chronic inflammatory states than the CRP concentra­
tion alone.
To gain a better understanding of the nature of the 
inflammatory response occurring in the hyper-IgD syn­
drome, the serum concentration of the acute-phase pro­
tein AGP and its type of glycosylation including the 
expression of SLeX were investigated in sera from pa­
tients with this syndrome, during both febrile attacks 
and remissions. Crossed affinoimmunoelectrophoresis 
(CAIE) was used to determine the presence of dianten­
nary containing glycoforms of AGP using concanavalin 
A (Con A) as affinocomponent in the first-dimension 
gel. The presence of glycoforms with a l —> 3 fucosy- 
lated glycans was determined using CAIE with Aleuria 
aurantia lectin (AAL) as affinocomponent. AAL is the 
only lectin to date that will react with the fucosylated 
lactosamine units present on AGP (15, 20, 21).
MATERIALS AND METHODS
Source of sera. Eleven patients (nine males, two fe­
males) suffering from the hyper-IgD syndrome were 
studied. The diagnosis was in accordance with the 
guidelines of the “International Hyper-IgD Study 
Group,” and these patients represented the numbers 2, 
5, 9,11,18, 21, 24, 26, 27, 35, and 36 in a recent clinical 
review (4). The mean age at the time of the attacks and 
collecting of blood was 30 years (range 13-69 years) 
and all patients were Dutch. Sampling of serum was 
performed during attacks and remissions. Attacks 
were defined when the patients were febrile >38°C (not 
caused by infection) and experiencing symptoms com­
patible with the hyper-IgD syndrome. Remission was 
defined as the complete absence of symptoms for at 
least 2 weeks. No medical treatment was allowed dur­
ing the study period. In addition, sera from two pa­
tients suffering from the hyper-IgD syndrome, who had 
been asymptomatic for at least 2 years, were studied. 
Sera were stored at -20°C until analysis. Sera from 
healthy individuals were used for the determination of 
control values.
(Glyco)protein concentration. Concentrations of 
CRP were determined by rocket immunoelectrophore­
sis according to Laurell (22), using rabbit anti-human 
CRP IgG (RAH-CRP-IgG) for precipitation. AGP con­
centrations were determined by single radial immuno­
diffusion, according to Mancini et al. (23), using mono- 
specific anti-human AGP IgG (RAH-AGP-IgG) for pre­
cipitation. All antibodies were purchased from 
Dakopatts, Glostrup, Denmark. Human serum C-reac­
tive protein (HS-CRP) calibrator, consisting of a delip- 
idated pool of human serum enriched in CRP, was used 
as a standard for the determination of the CRP con­
centration; according to the manufacturer’s informa­
tion the CRP concentration in this preparation was 
0.162 mg/ml. Human serum protein calibrator (HSPC), 
consisting of pooled sera from healthy blood donors, 
was used as a standard for the determination of the 
AGP concentration; according to the manufacturer’s 
information that AGP concentration in this prepara­
tion was 0.76 mg/ml. Both HSPC and HS-CRP calibra­
tor were from Dakopatts.
Crossed affinoim m unoelectrophoresis (CAIE). 
CAIE was performed according to the method of B0g- 
Hansen (24), using 2.5 mg/ml (with a hemagglutina­
tion titer of 512) Aleuria aurantia lectin (AAL) as the 
fucose-specific affino component, or 2 mg/ml concanav­
alin A as the diantennary-specific affinocomponent as 
described previously (15). AAL was isolated from fruit­
ing bodies of the Aleuria aurantia mushroom as de­
tailed earlier (15). In short, 0.5—2.0 ju,l of serum was 
electrophoresed through a lectin containing 1% aga­
rose gel, resulting in a separation of the differently 
glycosylated AGP forms. In the second, perpendicular 
dimension, these glycoprotein forms were immunoelec­
trophoresed against the precipitating monospecific an­
tiserum (RAH-AGP-IgG). The resulting precipitation 
curves were visualized by staining with Coomassie 
brilliant blue R250 (Sigma, St. Louis, MO). The areas
under the curves indicate the relative amounts of gly­
coprotein, which were determined using a Summa-
graph (ACECAD D-9000) coupled to a 386 SX PC 
equipped with an area measurement program (devel­
oped by D. Philips, Department of Physiology, Faculty 
of Medicine, Vrije Universiteit, Amsterdam, The Neth­
erlands).
Partial purification of AGP from serum and detection 
of SLeX-content of AGP. In order to obtain prepara­
tions enriched with AGP for a better interpretation of 
immunoblots, AGP was isolated from serum by immu- 
noaffinity chromatography, as described (25), using an 
anti-AGP-Sepharose 4B column. Serum (75-100 jul) 
was applied to the anti-AGP-Sepharose 4B column (0.8 
x 1.3 cm; 2 ml/hr). The glycosylation profiles of AGP 
before and after affinity purification were identical, in­
dicating that no glycosidases were present during the 
procedure. The concentration was determined by ra­
dial immunodiffusion, according to Mancini et al. (23). 
Ten percent SDS—PAGE was performed according to
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Laemmli (26) using the Mini Protean II dual slab gel 
apparatus from Bio-Rad. Gels were loaded with equal 
amounts of partially purified AGP; AGP isolated from 
Cohn fraction V from pooled normal human serum, a 
kind gift from Dr. D. H. van den Eijnden, was used as 
a standard. Proteins were blotted onto nitrocellulose by 
electrophoretic transfer using the Mini Transblot Cell 
from Bio-Rad. SLeX determinants on AGP were de­
tected as previously described (15) by incubating AGP 
containing nitrocellulose strips with mouse monoclonal
anti-SLeX IgM [CSLEX-1 (27) 25 jag/ml in 10 times 
diluted PBS; ATCC HB8580], followed by alkaline 
phosphatase-conjugated goat anti-mouse IgM (1:250 
dilution, Zymed, San Francisco, CA) for detection. An 
AAL-nonreactive fraction isolated from pooled normal 
human serum by means of preparative affinity electro­
phoresis (25) was used as a negative control.
Statistics. All values were tested for significance 
using the Student t test.
RESULTS
Concentrations of CRP and AGP in hyper-IgD sera. 
The CRP concentrations in the sera of hyper-IgD pa­
tients were below 0.02 mg/ml during remission and 
increased to 0.10—0.30 mg/ml during an attack. In con­
trast, the AGP concentrations during remission were 
higher than those in control sera (1.98 mg/ml compared 
to 0.79 mg/ml in control sera, P  < 0.05), with large 
interindividual differences. These concentrations in­
creased to an average value of 2.31 mg/ml during a 
febrile attack, also with large interindividual differ­
ences (Table 1). For the two patients who had been 
asymptomatic for at least 2 years, all protein concen­
trations had returned to control values (results not 
shown).
Reactivity of AGP with Con A and AAL. To estab­
lish whether changes in the diantennary glycan con­
tent and a l 3 fucosylation of AGP occurred in the 
sera of patients with the hyper-IgD syndrome during 
remission and febrile attacks, CAIE was performed 
with Con A and AAL as affinocomponents, respec­
tively. In Figs. lb, le, le, and If, precipitation curves of 
AGP are illustrated for one hyper-IgD patient, pro­
duced by CAIE with Con A and AAL, respectively. Dur­
ing a febrile attack, the reactivity with Con A was sig­
nificantly increased compared to control and remission 
values (P < 0.05), since the percentage of the Con A 
nonreactive fraction (CO) was decreased from 40.6% 
during remission to 35.3% during an attack (Table 1). 
The degree of reactivity ((C2 + C3)/C1) was concomi­
tantly increased from 0.37 during remission to 0.51 
during an attack. During remission, the reactivity of 
AGP with Con A returned to the control value (Ta­
ble 1).
The reactivity of AGP with AAL showed more dis­
tinct differences when compared to control values for 
both states of disease (Table 1). The degree of reactivity
((A3 + A4 + A5)/(A1 + A2)) of AGP with AAL for hy­
per-IgD patients was extremely high during both a fe­
brile attack (3.64) and remission (3.51). Although the 
values expressed large interindividual differences, 
they were significantly different from the degree of 
AAL reactivity of the control (0.92, P < 0.05). These 
increases in degree of reactivity corresponded with low 
percentages of unreactive component (A0) for AGP dur­
ing both remission (16.6%) and fever (15.8%) compared 
to the control value (38.0%). The glycosylation of AGP 
in the sera from patients who had been asymptomatic 
for at least 2 years had returned to control values, with 
respect to both the diantennary glycan content and the 
al —> 3 fucosylation (results not shown).
Expression of Sialyl Lewisx  (SLeX) on AGP in hyper- 
IgD sera. In order to determine if the increases in al 
—> 3 fucosylation also coincided with an increased ex­
pression of SLeX, partially purified AGP from 4 of the
TABLE 1
Concentrations of CRP and AGP and Reactivities with Con A and AAL of AGP in Hyper-IgD and Control Sera
> >.. , i .........i i . ^ >•' », ...... 1 • .1 > .................% . > 1 • I  >) > .................... r "»i ...................................... »ifi - »• I • Jm »IV ► * LI*. i.Ii u
ConA AAL
CRP AGP CO DR A0
(mg/ml) (mg/ml) n (%) (C2+C3VC1 (%)
Control
. »■-" —. s ‘ ‘ ^‘,1 -n,- If *14‘Afra
< 0 .0 2
|i«i.^«Ji »iM sL* V .  , imii ■ -“■ i*
0.79 ±0.17 10 46.0 ±8.0 0.33 ± 0.11 38.0 ± 13.0
HIgD—remission < 0 . 0 2 1.98 ± 0.72" 11 40.6 ±5.6 0.37 ± 0.10 16.6 ± 8 .2“
(1 1 /0 ) (0/ 1 1 ) (7/4) (9/2) ta (1/ 1 0 )
HIgD—fever 0.18 ± 0 .1 0 ,a 2.31 ±1.10" 11 35.3 ± 4.7a,ft 0.51 ± 0.15“’ 15.8 ± 8 .8 “lidr
(0 /1 1 ) (0/ 1 1 ) (2/9) (4/7) (3/8)
DR
( A3+A4+A5 )/( A1+A2 )
0.92 ± 0.36 
3.51 ±2.17“ 
(0 /11 ) 
3.64 ± 2.06“ 
(0/11)
Note. Values are given as the mean ± SD. DR, degree of reactivity; this is a measure for the intensity of the interaction between the lectin 
and AGP. The degrees of reactivity were determined by dividing the sum of the strongly reactive glycoforms by the sum of the moderately 
reactive glycoforms. CO and A0, fraction of AGP nonreactive with Con A and AAL, respectively. Values given in parentheses are the ratio of
values that fall within the control range over the values that fall outside it.
" Significantly different from contr< 
h Significantly different from HIgD •remission value P < 0.05.
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FIG. 1 . Reactivity of AGP with Con A (a-c) and AAL (d-f) in 
control serum (a,d) and hyper-IgD serum during remission (b,e) and 
during a febrile attack (c,f). Serum (0.5-2.0 /xl) from the same patient 
was subjected to CAIE as described under Materials and Methods. 
Only the second-dimension gels are shown. The lower right comer of 
each gel corresponds with the site of application in the first- 
dimension gel. Electrophoresis was performed in the directions right 
to left for the first dimension and bottom to top for the second di­
mension. CO and AO, AGP fractions that are nonreactive with Con 
A and AAL, respectively; C1-C 3  and A1-A5, forms of AGP that are 
increasingly reactive with Con A and AAL, respectively.
11 different patient sera (chosen at random) was sub­
jected to SDS—PAGE, blotted, and subsequently 
stained with a monoclonal antibody directed against 
SLeX (CSLEX-1). A representative Western blot of 
AGP isolated from one patient is shown in Fig. 2. Upon 
staining of AGP-containing nitrocellulose strips with 
CSLEX-1, a weak positive staining of AGP from sera 
obtained from healthy individuals was observed (Fig. 
2, lane 1). A strongly enhanced positive staining was 
observed for AGP isolated from hyper-IgD patients 
during remission and febrile attack (Fig. 2, lanes 3 and 
4, respectively), indicating a significant increase in the 
expression of SLeX on AGP in the hyper-IgD syn-
PIG. 2. Expression of SLeX on partially purified AGP from hy­
per-IgD sera. Equal amounts of affinity-purified AGP [3 fig as deter­
mined by radial immunodiffusion (23)] were subjected to SDS- 
PAGE, subsequent blotting, and detection of SLeX with a specific 
monoclonal antibody (CSLEX-1 ) as described under Materials and 
Methods. A representative Western blot of AGP from one hyper-IgD 
patient is shown; only the part of the blot containing AGP bands is 
reproduced, 1 , AGP from control serum; 2 , AGP nonreactive with 
AAL; 3, AGP from hyper-IgD serum during remission; 4, AGP from 
hyper-IgD serum during an attack.
drome. No staining was observed for an AAL- 
nonreactive fraction isolated from the serum of healthy 
individuals (Fig. 2, lane 2), which was used as a nega­
tive control.
DISCUSSION
Although the hyper-IgD syndrome is characterized 
by short febrile attacks followed by apparently asymp­
tomatic intervals, the present study is indicative of 
both acute and chronic inflammatory responses within 
this disease. The concentration of the acute phase pro­
tein AGP is significantly increased during both febrile 
attacks and remissions, as compared to concentrations 
in serum of healthy individuals. The concentration of 
CRP is increased only during febrile attacks. The a l -> 
3 fucosylation of AGP, as indicated by the high reac­
tivity with AAL and the CSLEX-1 staining, in serum of 
hyper-IgD patients is increased during both attacks 
and remissions. The increases in a l —> 3 fucosylation 
are extreme compared to the value for healthy individ­
uals, with a concomitant increased expression of SLeX. 
Previously, it has been shown that for chronic inflam­
mation such as rheumatoid arthritis, the percentage of 
nonfucosylated AGP (AO) was approximately 18 (17), 
whereas for acute inflammation induced by laparoto­
my, this percentage was found to be approximately 30 
(15). Therefore, the low percentages of nonfucosylated 
AGP (AO) continuously present in hyper-IgD patients 
are compatible with chronic inflammation. The contin­
uously high a l —> 3 fucosylation in rheumatoid arthri­
tis can be decreased by treatment with methotrexate, 
and this coincides with a decrease in disease activity 
(17). Possibly, the relatively high frequency of febrile 
attacks (once every 4-8 weeks) in the hyper-IgD syn­
drome does not allow the a l —» 3 fucosylation to return 
to a basic level, since after an asymptomatic period of 2 
years, the concentrations of CRP and AGP and the gly­
cosylation of AGP returned to control values. This 
would be in agreement with our previous finding that 
in the case of severe bums, the a l 3 fucosylation can 
remain extremely high for at least 30 days after the 
event (15), indicating a persistent state of inflamma­
tion.
With respect to the Con A reactivity of AGP, signif­
icant increases occurred during a febrile attack, re­
turning to control values during remission. These in­
creases in Con A reactivity of AGP may be interpreted 
as increases in diantennary glycan content, since it has 
previously been shown that the glycans of AGP are of a 
complex type, in both healthy and diseased states (9). 
This supports the previous findings that the febrile at­
tack is accompanied by an acute phase response, which 
is further corroborated by the steeply elevated CRP 
plasma concentrations found in these patients during 
attacks.
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In conclusion, our studies indicate that the hyper- 
D syndrome seems to be a disorder of persistent in­
cultures of human hepatocytes and transgenic mice. Biochem. J. 
276, 343-347, 1991.
flammation 9. Analysis
as does the cel
remissions
of AGP
inflammation
of CRP
does the diantennary glycan content of AGP, indicating
of inflammation
inflamed
rheumatoid
but are unique for
like the hyper-IgD syndrome. Proinflaramatory c; 
kines (IL-1, IL-6, TNF) have been shown to modify 
glycosylation of acute phase proteins such as AGP ( 
14). The changes reported here for the hyper-IgD s
drome
this syndrome
ACKNOWLEDGMENTS
This work was supported by the Dutch Organization for Scientific
the five glycosylation sites of human a -^acid glycoprotein. Bio­
chem. J. 282, 1- 6 , 1992.
10. Mackiewicz, A., Pawlowski, T., Mackiewicz-Pawlowska, A., Wik- 
torowicz, K., and Mackiewicz, S., Microheterogeneity forms of 
a x-acid glycoprotein as indicators of rheumatoid arthritis activ­
ity. Clin. Chim. Acta 163, 185-190, 1987.
11. Pawlowski, T., and Mackiewicz, A., Minor microheterogeneity of 
a , -acid glycoprotein in rheumatoid arthritis. In “Alpha! Acid 
Glycoprotein: Genetics, Biochemistry, Physiological Functions 
and Pharmacology” (P. Baumann, C. B. Eap, W. E. Muller, and 
J.-P. Tillement, Eds.), pp. 223-226, A. R. Liss, New York, 1989.
1 2 . Pos, O., Moshage, H. J., Yap, S. H., Snieders, J. P. M., Aarden, 
L. A., Van Gooi, J., Boers, W., Brugman, A. M., and Van Dijk, 
W., Effects of monocytic products, recombinant interleukin-1 , 
and recombinant interleukin-6  on glycosylation of a x-acid glyco­
protein: Studies with primary human hepatocyte cultures and 
rats. Inflammation 13, 415-427, 1989.
13. Mackiewicz, A., Schultz, D., Mathison, J., Ganapathi, M., and 
Kushner, I., Effect of cytokines on glycosylation of acute phase 
proteins in human hepatoma cell lines. Clin. Exp. Immunol. 75, 
70-75, 1989.
Research (NWO 900-512-164). J. P. H. Drenth is a recipient of a 1 4  Mackiewicz, A., Laciak, M., Gorny, A., and Baumann, H., Leu-
Dutch Organization for Scientific Research Fellowship for Clinical 
Investigators (KWO 900-716-065). Professor Dr. D. H. van den 
Eijnden is acknowledged for his stimulating discussions and critical 
reading of the manuscript. Mr. Han Verbeek is acknowledged for his 
help in the preparation of the figures.
REFERENCES
1 . Van der Meer, J. W. M., Radi, J., Meyer C. J. L. M., Vossen, 
J. M., Van Nieuwkoop, J. A., Lobatto, S., and Van Furth, R., 
Hyperimmunoglobulinemia D and periodic fever: A new syn­
drome. Lancet i, 1087-1090, 1984.
2 . Hiematra, I., Vossen, J. M., Van der Meer, J. W. M.,
immuC., Out, Th. A., and Zegera, B. J., Clini
oh in an increased serum
Immunol. 9, 393-400, 1989.
3. Drenth, J. P.
J. W. M., C
the hyperim
per-
, B. W., Toonstra, J., and Van der Meer, 
ou» manifestations and histologic findings in
inemia I) syndrome. International Hy- 
Group. Arch. Dermatol. 130, 59-65, 1994.
kemia inhibitory factor, interferon gamma, and dexamethasone 
regulate N-glycosylation of ax-protease inhibitor. Eur. J. Cell
Biol. 60, 331-336, 1993.
15. de Graaf, T. W., Van der Stelt, M. E., Anbergen, M. G., and Van 
Dijk, W., Inflammation induced expression of sialyl Lewis X con­
taining glycan structures on «1-acid glycoprotein (orosomucoid) 
in human sera. J. Exp. Med. 177, 657-666, 1993.
16. Van der Linden, E. C. M., de Graaf, T. W., Anbergen, M. G., Van 
Ommen, E. C. R., Van der Stelt, M. E., and Van Dijk, W., Ex­
pression of sialyl Lewis X groups on human c^-acid glycoprotein 
in acute and chronic inflammation. Glycoconj. J. 10, 316-317, 
1993.
17. de Graaf, T. W., Van Ommen, E. C. R., Van der Stelt, M. E., 
Kerstens, P. J. S. M., Boerbooms, A. M. Th., and Van Dijk, W., 
Effects of low dose methotrexate therapy on the concentration 
and the glycosylation of ax-acid glycoprotein in the serum of 
rheumatoid arthritis patients: A longitudinal study. J. Rheuma­
tol. 2 1 , 2209-2216, 1994.
4.
o*
glycosylation of acuto-pham
c u r r e n c y
uiho: 'm
is. 1, 5-14,
'I*
8.
, «J. P. H., Hnagmtm, C. J., Van der Meer, J. W. M., and ^  Thompson, S., Kelly, C. A., Griffiths, I. D., and Turner, G. A., 
International Hyper-IgD Study Group, Hyperimmunoglobu- Abnormally fucosylated serum haptoglobins m patients with in- 
mia I) and periodic Jbver nyndromo: The clinical spectrum in flammatory joint disease. Clm. Chim. Acta 184, 251—2o8, 1989.
a series of 50 patients. Medicine {Baltimore) 78, 133-144, 1994. 1 9 , Thompson, S., and Turner, G. A., Elevated levels of abnormally
ijk, W., Turner, (i. A., anti Mackiewicz, A,, Changes in the fucosylated haptoglobins in cancer sera. Br. J. Cancer 56, 605-
610, 1987.
2 0 . Yamashita, K., Kochibe, N., Okhura, T., Ueda, L, and Kobata, 
A., Fractionation of L-fucose-containing oligosaccharides on im­
mobilized Aleuria aurantia lectin. J. Biol. Chem. 260, 4688—
4693, 1985.
21. Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Hav­
erkamp, J., Vliegenthart, J. F. G., Binette, J. P., and Schmid, K., 
Determination of the primary structure of 16 asialo- 
carbohydrate units derived from human plasma «j-acid glyco­
protein by 360-MHz lH NMR spectroscopy and permethylation 
analysis. Biochemistry 17, 5206-5214, 1978.
22. Laurell, C. B., Quantitative estimation of protein by electropho­
resis in agarose gel containing antibodies. Anal. Biochem. 15, 
45-52, 1966.
6 . Nicollet, I., Lebreton, J. P., Fontaine, M., and Hiron, M., Evi­
dence for «,-acid glycoprotein populations of different p/ values
after concanavalin A affinity chromatography: Study of their 
evolution in inflammation in man. Biochim. Biophys. Acta 6 6 8 ,
235-245, 1981.
7. Drechou, A., Perez-Gonzalez, N., Agneray, J., Feger, J., and Du­
rand, G., Increased affinity to concanavalin A and enhanced se­
cretion of -acid glycoprotein by hepatocytes isolated from tur­
pentine-treated rats. Eur. J. Cell . 50, 111-1
, w . , , ()., Van der Stell, M. E.,
S. H., Dente, L., Baumann, P., 
induced changes in expmwion 
ants of «i-acid glycoprotein: Studies with
<e, H. J., Yap,
B., Inflammation 
of genetic vari-
sera, primary 23. Mancini, G., Carbonara, A. O., and Heremans, J. F., A single
284 HAVENAAR ET AL
radial diffusion method for the immunological quantitation of 
proteins. Immunochemistry 2 , 235-254, 1965.
24. B0g-Hansen, T. C., Crossed immunoaffinoelectrophoresis: An 
analytical method to predict the result of affinity chromatogra­
phy. Anal. Biochem. 56, 480-488, 1973.
25. Van der Linden, E. C. M., de Graaf, T. W., Anbergen, M. G., De­
kker, R. M., Van Ommen, E. C. R., Van den Eijnden, D. H., and 
Van Dijk, W., Preparative affinity electrophoresis of different 
glycoforms of serum glycoproteins: Application for the study of 
inflammation-induced expression of Sialyl Lewisx groups on c -^
Received January 4, 1995; accepted with revision May 9, 1995
acid glycoprotein (orosomucoid). Glycosylation Dis. 1, 45-52, 
1994.
26. Laemmli, U. K., Cleavage of structural proteins during the as­
sembly of the head of bacteriophage T4. Nature 227, 680-685, 
1970.
27. Fukushima, K., Hirota, M., Terasaki, P. I., Wakisaka, A., To- 
gashi, H., Chia, D., Suyama, N., Fukushi, Y., Nudelman, E., and 
Hakomori, S. I., Characterization of sialysolated Lewisx as a 
new tumor associated antigen. Cancer Res. 4 4 ,5279-5285,1984.
